.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
Daiichi Sankyo
Federal Trade Commission
Novartis
US Army
Fuji
Teva
Deloitte
Fish and Richardson

Generated: December 14, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,187,791

« Back to Dashboard

Claims for Patent: 6,187,791

Title: Method of providing an antihistaminic effect in a hepatically impaired patient
Abstract:The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2; n is an integer of from 1 to 5; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
Inventor(s): Woodward; James K. (Cincinnati, OH), Okerholm; Richard A. (West Chester, OH), Eller; Mark G. (Overland Park, KS), McNutt; Bruce E. (Olathe, KS)
Assignee: Merrell Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:09/481,404
Patent Claims: 1. A method of treating a histaminic-mediated condition in a patient in need thereof but susceptible to possible cardiac events associated with the administration of terfenadine, said method comprising administering to said patient an effective antihistaminic amount of a compound of the formula: ##STR3##

wherein

R.sub.1 is hydrogen or hydroxy;

R.sub.2 is hydrogen;

or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2;

n is an integer of from 1 to 5;

R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched;

each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen;

or a pharmaceutically acceptable salt and individual enantiomers thereof.

2. A method of claim 1 wherein the compound is 4-[1-hydroxy-4-[4-(hydroxydiphenymethyl)-1-piperidinyl]butyl]-.alpha.,.alp ha.-dimethyl benzeneacetic acid.

3. A method of claim 1 wherein the compound is (R)--4-[1 -hydroxy-4-[4-hydroxydiphenylmethyl)-1 -piperidinyl]butyl]-.alpha.,.alpha.-dimethyl benzeneacetic acid.

4. A method of claim 1 wherein the compound is (S)-4-[1-hydroxy-4[4-hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,. alpha.-dimethyl benzeneacetic acid.

5. A method of treating a histamine-mediated disease in a human while avoiding the concomitant liability of cardiac arrhythmias associated with the administration of terfenadine, comprising administering to said human a therapeutically effective amount of racemic terfenadine carboxylate or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 wherein the amount of racemic terfenadine carboxylate administered is from about 20 mg to about 800 mg per day.

7. The method of claim 6 wherein the amount of racemic terfenadine carboxylate administered is from about 40 mg to about 360 mg per day.

8. The method of claim 5 wherein the amount of said racemic terfenadine carboxylate or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.

9. In a method of providing an antihistaminic effect in a patient susceptible to QT prolongation and/or ventricular tachycardia when using terfenadine, the improvement which comprises administering to said patient an effective amount of a compound of the formula: ##STR4##

wherein

R.sub.1 is hydrogen or hydroxy;

R.sub.2 is hydrogen;

or R.sub.1 and R2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2;

n is an integer of from 1 to 5;

R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched;

each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen;

or a pharmaceutically acceptable salt and individual enantiomers thereof.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Colorcon
Farmers Insurance
Express Scripts
Boehringer Ingelheim
Chubb
Dow
UBS
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot